Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1434028 | 0.83 | ADORA3 (0.49) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL7793907 | 0.79 | ADORA3 (0.61) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL23620984 | 0.74 | ADORA3 (0.45) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL9491636 | 0.73 | ADORA3 (0.47) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL7165627 | 0.72 | ADORA3 (0.44) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL3514758 | 0.72 | SLC28A2 (0.45) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL30313460 | 0.72 | CYP1A2 (0.31) | — | |
| SCHEMBL27687690 | 0.71 | CD99 (0.47) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL13268870 | 0.71 | ADORA2A (0.41) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL9341012 | 0.71 | PI4KA (0.43) | ADORA3ADORA1ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130064816-A1 | TNF-alpha ANTAGONISTS AND METHOTREXATE IN THE TREATMENT OF TNF-MEDIATED DISEASE | THE MATHILDA AND TERENCE KENNEDY INSTITUTE OF RHEUMATOLOGY TRUST | 2013-03-14 | — | — | US | disclosed |
| US-8383120-B2 | Concomitant treatment of rheumatoid arthritis with anti-TNF-alpha antibodies and methotrexate | THE MATHILDA AND TERENCE KENNEDY INSTITUTE OF RHEUMATOLOGY TRUST (GB) | 2013-02-26 | — | — | US | disclosed |
| US-8298537-B2 | Concomitant treatment of rheumatoid arthritis with anti-TNF-α antibodies and methotrexate | THE MATHILDA AND TERENCE KENNEDY INSTITUTE OF RHEUMATOLOGY TRUST (GB) | 2012-10-30 | — | — | US | disclosed |
| US-20120141475-A1 | TNF-alpha Antagonists and Methotrexate in the Treatment of TNF-Mediated Disease | THE MATHILDA AND TERENCE KENNEDY INSTITUTE OF RHEUMATOLOGY TRUST | 2012-06-07 | — | — | US | disclosed |
| US-20120141474-A1 | TNF-alpha Antagonists and Methotrexate in the Treatment of TNF-Mediated Disease | THE MATHILDA AND TERENCE KENNEDY INSTITUTE OF RHEUMATOLOGY TRUST | 2012-06-07 | — | — | US | disclosed |
| US-20110014188-A1 | TNFalpha antagonists and methotrexate in the treatment of TNF-mediated disease | The Kennedy Institute of Rheumotology | 2011-01-20 | — | — | US | disclosed |
| US-7838489-B2 | Methods of treating rheumatoid arthritis with p75 TNF-alpha receptor and methotrexate | THE MATHILDA AND TERENCE KENNEDY INSTITUTE OF RHEUMATOLOGY TRUST (GB) | 2010-11-23 | — | — | US | disclosed |
| US-7608262-B2 | Methods of preventing or treating thrombosis with tumor necrosis factor antagonists | THE KENNEDY INSTITUTE OF RHEUMATOLOGY (GB) | 2009-10-27 | — | — | US | disclosed |
| US-20090263388-A1 | Methods of preventing or treating cardiovascular, cerebrovascular and thrombotic disorders with tumor necrosis factor antagonists | THE KENNEDY INSTITUTE OF RHEUMATOLOGY | 2009-10-22 | — | — | US | disclosed |
| US-20090175859-A1 | TNFalpha antagonists and methotrexate in the treatment of TNF-mediated disease | THE KENNEDY INSTITUTE OF RHEUMATOLOGY | 2009-07-09 | — | — | US | disclosed |
| EP-0936923-A1 | SUPPRESSION OF TNF $g(a) AND IL-12 IN THERAPY | KENNEDY INSTITUTE OF RHEUMATOLOGY (GB) | 1999-08-25 | — | — | EP | disclosed |
| EP-0914157-A1 | ANTI-TNF ANTIBODIES AND METHOTREXATE IN THE TREATMENT OF AUTOIMMUNE DISEASE | THE KENNEDY INSTITUTE OF RHEUMATOLOGY (GB) | 1999-05-12 | — | — | EP | disclosed |
| EP-0882067-A2 | METHODS OF TREATING VASCULAR DISEASE WITH TNF ANTAGONISTS | THE KENNEDY INSTITUTE OF RHEUMATOLOGY (GB) | 1998-12-09 | — | — | EP | disclosed |
| WO-1998039008-A1 | METHODS AND COMPOSITIONS FOR PROTECTING AGAINST CARDIAC ISCHEMIA BY ADMINISTERING ADENOSINE A2A RECEPTOR ANTAGONISTS | TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1998-09-11 | — | — | WO | disclosed |
| WO-1998022137-A1 | SUPPRESSION OF TNF α AND IL-12 IN THERAPY | THE KENNEDY INSTITUTE OF RHEUMATOLOGY (GB) | 1998-05-28 | — | — | WO | disclosed |
| WO-1998005357-A1 | ANTI-TNF ANTIBODIES AND METHOTREXATE IN THE TREATMENT OF AUTOIMMUNE DISEASE | THE KENNEDY INSTITUTE OF RHEUMATOLOGY (GB) | 1998-02-12 | — | — | WO | disclosed |
| WO-1997030088-A2 | METHODS OF TREATING VASCULAR DISEASE WITH TNF ANTAGONISTS | THE KENNEDY INSTITUTE OF RHEUMATOLOGY (GB) | 1997-08-21 | — | — | WO | disclosed |
| EP-0383759-A4 | N?6 -SUBSTITUTED 9-METHYLADENINES: A NEW CLASS OF ADENOSINE RECEPTOR ANTAGONISTS | — | 1993-03-17 | — | — | EP | disclosed |
| EP-0383759-A1 | N6 SUBSTITUTED 9-METHYLADENINES: A NEW CLASS OF ADENOSINE RECEPTOR ANTAGONISTS | Whitby Research Incorporated (US) | 1990-08-29 | — | — | EP | disclosed |
| WO-1988008303-A1 | N6-SUBSTITUTED 9-METHYLADENINES: A NEW CLASS OF ADENOSINE RECEPTOR ANTAGONISTS | NELSON RESEARCH AND DEVELOPMENT COMPANY (US) | 1988-11-03 | — | — | WO | disclosed |